Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery

References

• Abidi AJJop, pharmacotherapeutics. 2013. Cabazitaxel: a novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother. 4(4):230–237.
   PubMedGoogle Scholar
• Darby RAJ, Callaghan R, McMahon RM. 2011. P-glycoprotein inhibition: the past, the present and the future. Curr Drug Metab. 12(8):722–731.
   PubMed Web of Science ®Google Scholar
• Alahari SK, DeLong R, Fisher MH, Dean NM, Viliet P, Juliano R. 1998. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. Therapeutics E. 286(1):419–428.
   PubMed Web of Science ®Google Scholar
• Al-Akra L, Bae D-H, Sahni S, Huang ML, Park KC, Lane DJ, Jansson PJ, Richardson D. 2018. Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones. J Biol Chem. 293(10):3562–3587.
   PubMed Web of Science ®Google Scholar
• Alfarouk KO, Stock C-M, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO, Harguindey S. 2015. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. 15(1):1–13.
   Google Scholar
• Altmann K-H, Wartmann M, O’Reilly T. 2000. Epothilones and related structures–a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 1470(3):M79–91.
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman M. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 39(1):361–398.
   PubMed Web of Science ®Google Scholar
• Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano R. 2000. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol. 60(1):83–90.
   PubMed Web of Science ®Google Scholar
• Bailey D, Spence J, Munoz C, Arnold JJTL. 1991. Interaction of citrus juices with felodipine and nifedipine. Lancet. 337(8736):268–269.
   PubMed Web of Science ®Google Scholar
• Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. 2009. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today. 14(21–22):1067–1074.
   PubMed Web of Science ®Google Scholar
• Bansal T, Jaggi M, Khar R, Talegaonkar S, Sciences P. 2009. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci. 12(1):46–78.
   PubMed Web of Science ®Google Scholar
• Barker TJ, Duncan KK, Otrubova K, Boger D. 2013. Potent vinblastine C20′ ureas displaying additionally improved activity against a vinblastine-resistant cancer cell line. ACS Med Chem Lett. 4(10):985–988.
   PubMed Web of Science ®Google Scholar
• Bar-Zeev M, Livney YD, Assaraf Y. 2017. Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance. Drug Resist Updat. 31:15–30.
   PubMed Web of Science ®Google Scholar
• Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods C. 1995. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55(11):2325–2333.
   PubMed Web of Science ®Google Scholar
• Bouchet BP, Galmarini C. 2010. Cabazitaxel, a new taxane with favorable properties. Drugs Today. 46(10):735–742.
   PubMed Web of Science ®Google Scholar
• Bradley G, Ling V. 1994. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 13(2):223–233.
   PubMed Web of Science ®Google Scholar
• Callaghan R, Luk F, Bebawy MJDM. 2014. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos. 42(4):623–631.
   PubMed Web of Science ®Google Scholar
• Calvaresi EC, Hergenrother P. 2013. Glucose conjugation for the specific targeting and treatment of cancer. Chem Sci. 4(6):2319–2333.
   PubMed Web of Science ®Google Scholar
• Chang P-Y, Peng S-F, Lee C-Y, Lu C-C, Tsai S-C, Shieh T-M, Wu T-S, Tu M-G, Chen MY, Yang J-S. 2013. Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells. Int J Oncol. 43(4):1141–1150.
   PubMed Web of Science ®Google Scholar
• Chang TK, Yu L, Maurel P, Waxman D. 1997. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 57(10):1946–1954.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tang Y, Wang M-T, Zeng S, Nie DJCr. 2007. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res. 67(21):10361–10367.
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Chen ZG, Shin DM. 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 14(5):1310–1316.
   PubMed Web of Science ®Google Scholar
• Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. 2002. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62(12):3387–3394.
   PubMed Web of Science ®Google Scholar
• Cui J, Liu X, Chow L. 2019. Flavonoids as P-gp inhibitors: a systematic review of SARs. Curr Med Chem. 26(25):4799–4831.
   PubMed Web of Science ®Google Scholar
• Dallavalle S, Dobričić V, Lazzarato L, Gazzano E, Machuqueiro M, Pajeva I, Tsakovska I, Zidar N, Fruttero R. 2020. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist Updat. 50:100682.
   PubMed Web of Science ®Google Scholar
• de Jonge ME, Huitema AD, van Dam SM, Beijnen JH, Rodenhuis S. 2005. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol. 55(5):507–510.
   PubMed Web of Science ®Google Scholar
• Drinberg V, Bitcover R, Rajchenbach W, Peer DJCl. 2014. Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine. Cancer Lett. 354(2):290–298.
   PubMed Web of Science ®Google Scholar
• Ekins S, Chang C, Mani S, Krasowski MD, Reschly EJ, Iyer M, Kholodovych V, Ai N, Welsh WJ, Sinz M, et al. 2007. Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol. 72(3):592–603.
   PubMed Web of Science ®Google Scholar
• Ekins S, Erickson J. 2002. A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos. 30(1):96–99.
   PubMed Web of Science ®Google Scholar
• Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A. 2004. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther. 75(5):448–454.
   PubMed Web of Science ®Google Scholar
• Esser L, Zhou F, Pluchino KM, Shiloach J, Ma J, Tang W-K, Gutierrez C, Zhang A, Shukla S, Madigan JP, et al. 2017. Structures of the multidrug transporter p-glycoprotein reveal asymmetric ATP binding and the mechanism of polyspecificity. J Biol Chem. 292(2):446–461.
   PubMed Web of Science ®Google Scholar
• Etievant C, Barret J-M, Kruczynski A, Perrin D, Hill B. 1998. Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs. 16(1):3–17.
   PubMed Web of Science ®Google Scholar
• Evans A. 2000. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit. 22(1):131–136.
   PubMed Web of Science ®Google Scholar
• Filipits M, Stranzl T, Pohl G, Heinzl H, Jäger U, Geissler K, Fonatsch C, Haas O, Lechner K, Pirker RJL. 2000. Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia. 14(1):68–76.
   PubMed Web of Science ®Google Scholar
• Fruttero R, Crosetti M, Chegaev K, Guglielmo S, Gasco A, Berardi F, Niso M, Perrone R, Panaro MA, Colabufo NA. 2010. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. J Med Chem. 53(15):5467–5475.
   PubMed Web of Science ®Google Scholar
• Gacche RN, Assaraf Y. 2018. Redundant angiogenic signaling and tumor drug resistance. Drug Resist Updat. 36:47–76.
   PubMed Web of Science ®Google Scholar
• Gao YD, Olson SH, Balkovec JM, Zhu Y, Royo I, Yabut J, Evers R, Tan EY, Tang W, Hartley DP, et al. 2007. Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica. 37(2):124–138.
   PubMed Web of Science ®Google Scholar
• Gillam EM, Guo ZY, Martin MV, Jenkins CM, Guengerich F. 1995. Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch Biochem Biophys. 319(2):540–550.
   PubMed Web of Science ®Google Scholar
• Gottesman M. 2002. Mechanisms of cancer drug resistance. Annu Rev Med. 53(1):615–627.
   PubMed Web of Science ®Google Scholar
• Gupta D, Venkatesh M, Wang H, Kim S, Sinz M, Goldberg GL, Whitney K, Longley C, Mani S. 2008. Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin Cancer Res. 14(17):5332–5340.
   PubMed Web of Science ®Google Scholar
• Hamilton M, Wolf JL, Drolet DW, Fettner SH, Rakhit AK, Witt K, Lum BL. 2014. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemother Pharmacol. 73(3):613–621.
   PubMed Web of Science ®Google Scholar
• Harmsen S, Meijerman I, Beijnen J, Schellens J. 2007. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev. 33(4):369–380.
   PubMed Web of Science ®Google Scholar
• Harmsen S, Meijerman I, Febus C, Maas-Bakker R, Beijnen J, Schellens JJCc. 2010. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 66(4):765–771.
   PubMed Web of Science ®Google Scholar
• Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel A. 2013. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int J Cancer. 132(10):2439–2447.
   PubMed Web of Science ®Google Scholar
• Iwahashi T, Okochi E, Ariyoshi K, Watabe H, Amann E, Mori S, Tsuruo T, Ono K. 1993. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res. 53(22):5475–5482.
   PubMed Web of Science ®Google Scholar
• Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, Shu YJMc. 2019. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 18(1):1–15.
   PubMed Web of Science ®Google Scholar
• Kingston D, Newman D. 2007. Taxoids: cancer-fighting compounds from nature. Curr Opin Drug Discov Devel. 10(2):130–144.
   PubMedGoogle Scholar
• Köhler G, Bode-Böger S, Busse R, Hoopmann M, Welte T, Böger R. 2000. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 38(11):504–513.
   PubMed Web of Science ®Google Scholar
• Kopecka J, Trouillas P, Gašparović AČ, Gazzano E, Assaraf YG, Riganti C. 2020. Phospholipids and cholesterol: inducers of cancer multidrug resistance and therapeutic targets. Drug Resist Updat. 49:100670.
   PubMed Web of Science ®Google Scholar
• Kumar SP, Sherpa DD, Sahu AK, Jadav T, Tekade RK, Sengupta P. 2021. Innovation in bioanalytical strategies and in vitro drug-drug interaction study approaches in drug discovery. Bioanalysis. 13(6):513–532.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, Yang D-H, Chen Z-S. 2016. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat. 27:14–29.
   PubMed Web of Science ®Google Scholar
• Lin J. 2003. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev. 55(1):53–81.
   PubMed Web of Science ®Google Scholar
• Lindley C, Hamilton G, McCune JS, Faucette S, Shord SS, Hawke RL, Wang H, Gilbert D, Jolley S, Yan B, et al. 2002. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 30(7):814–822.
   PubMed Web of Science ®Google Scholar
• Lo Y-L, Liu Y, Tsai J-C. 2013. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo. Biomed Pharmacother. 67(4):261–267.
   PubMed Web of Science ®Google Scholar
• Loose D, Stover E, Feldman D. 1983. Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. J Clin Invest. 72(1):404–408.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV. 2003. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 101(6):2368–2373.
   PubMed Web of Science ®Google Scholar
• Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, Schellens J. 2001. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol. 19(4):1160–1166.
   PubMed Web of Science ®Google Scholar
• Mani S, Dou W, Redinbo M. 2013. PXR antagonists and implication in drug metabolism. Drug Metab Rev. 45(1):60–72.
   PubMed Web of Science ®Google Scholar
• Marchetti S, Mazzanti R, Beijnen JH, Schellens J. 2007. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 12(8):927–941.
   PubMed Web of Science ®Google Scholar
• Masuyama H, Hiramatsu Y, Kodama J-i, Kudo T. 2003. Expression and potential roles of pregnane X receptor in endometrial cancer. J Clin Endocrinol Metab. 88(9):4446–4454.
   PubMed Web of Science ®Google Scholar
• Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T, Hiramatsu Y. 2005. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol. 19(5):1170–1180.
   PubMedGoogle Scholar
• Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa A. 1989. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells. Cancer Res. 49(12):3209–3214.
   PubMed Web of Science ®Google Scholar
• Modiwala M, Jadav T, Sahu AK, Tekade RK, Sengupta P. 2021. A critical review on advancement in analytical strategies for the quantification of clinically relevant biological transporters. Crit Rev Anal Chem. 2021:1–15.
   Web of Science ®Google Scholar
• Montesinos RN, Béduneau A, Pellequer Y, Lamprecht A. 2012. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J Control Release. 161(1):50–61.
   PubMed Web of Science ®Google Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, et al. 2008. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 36(2):205–216.
   PubMed Web of Science ®Google Scholar
• Motomura S, Motoji T, Takanashi M, Wang YH, Shiozaki H, Sugawara I, Aikawa E, Tomida A, Tsuruo T, Kanda N, et al. 1998. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood. 91(9):3163–3171.
   PubMed Web of Science ®Google Scholar
• Murakami T, Takano M. 2008. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol. 4(7):923–939.
   PubMed Web of Science ®Google Scholar
• Murray G, McFadyen M, Mitchell R, Cheung Y, Kerr A, Melvin W. 1999. Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer. 79(11–12):1836–1842.
   PubMed Web of Science ®Google Scholar
• Najar I, Sachin B, Sharma S, Satti N, Suri K, Johri R. 2010. Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother Res. 24(3):454–458.
   PubMed Web of Science ®Google Scholar
• Nakanishi TJCg, proteomics. 2007. Drug transporters as targets for cancer chemotherapy. Cancer Genomics Proteomics. 4(3):241–254.
   PubMedGoogle Scholar
• Nallani SC, Goodwin B, Maglich JM, Buckley DJ, Buckley AR, Desai P. 2003. Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor. Drug Metab Dispos. 31(5):681–684.
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Mazzei T, Mini E. 2012. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev. 32(6):1220–1262.
   PubMed Web of Science ®Google Scholar
• Oyama T, Morita M, Isse T, Kagawa N, Nakata S, So T, Mizukami M, Ichiki Y, Ono K, Sugaya MJFB. 2005. Immunohistochemical evaluation of cytochrome P450 (CYP) and p53 in breast cancer. Front Biosci. 10(1–3):1156–1161.
   PubMed Web of Science ®Google Scholar
• Parhi P, Mohanty C, Sahoo S. 2012. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today. 17(17–18):1044–1052.
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem M. 2001. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem. 268(24):6346–6358.
   PubMedGoogle Scholar
• Qian J, Xu M, Suo A, Xu W, Liu T, Liu X, Yao Y, Wang HJAb. 2015. Folate-decorated hydrophilic three-arm star-block terpolymer as a novel nanovehicle for targeted co-delivery of doxorubicin and Bcl-2 siRNA in breast cancer therapy. Acta Biomater. 15:102–116.
   PubMed Web of Science ®Google Scholar
• Raz S, Sheban D, Gonen N, Stark M, Berman B, Assaraf YJCd. 2014. Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest. Cell Death Dis. 5(2):e1067.
   PubMed Web of Science ®Google Scholar
• Reddy A, Jadav T, Sahu AK, Sengupta P. 2022. LC-MS/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction. Bioanalysis. 14(2):75–86.
   PubMed Web of Science ®Google Scholar
• Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia AJCr. 2005. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 65(2):516–525.
   PubMed Web of Science ®Google Scholar
• Robinson K, Tiriveedhi V. 2020. Perplexing role of P-glycoprotein in tumor microenvironment. Front Oncol. 10:265.
   PubMed Web of Science ®Google Scholar
• Roy P, Waxman DJ. 2006. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol In Vitro. 20(2):176–186.
   PubMed Web of Science ®Google Scholar
• Sahu AK, Sengupta P. 2020. Time of flight mass spectrometry based in vitro and in vivo metabolite profiling of ribociclib and their toxicity prediction. J Chromatogr B Analyt Technol Biomed Life Sci. 1147:122142.
   PubMed Web of Science ®Google Scholar
• Saneja A, Dhar Dubey R, Alam N, Khare V, N Gupta P. 2014. Co-formulation of P-glycoprotein substrate and inhibitor in nanocarriers: an emerging strategy for cancer chemotherapy. Curr Cancer Drug Targets. 14(5):419–433.
   PubMed Web of Science ®Google Scholar
• Schellens JH, Malingré MM, Kruijtzer CMF, Bardelmeijer H, van Tellingen O, Schinkel AH, Beijnen J. 2000. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci. 12(2):103–110.
   PubMed Web of Science ®Google Scholar
• Scott AM, Rosa E, Mehta BM, Divgi CR, Finn RD, Biedler JL, Tsuruo T, Kalaigian H, Larson SM. 1995. In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody. Nucl Med Biol. 22(4):497–504. eng.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich F. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Therapeutics E. 270(1):414–423.
   PubMed Web of Science ®Google Scholar
• Sinha BK, Bortner CD, Mason RP, Cannon RE. 2018. Nitric oxide reverses drug resistance by inhibiting ATPase activity of p-glycoprotein in human multi-drug resistant cancer cells. Biochim Biophys Acta Gen Subj. 1862(12):2806–2814.
   PubMed Web of Science ®Google Scholar
• Sinz M. 2008. Pregnane X receptor: prediction and attenuation of human CYP3A4 enzyme induction and drug–drug interactions. Mol Pharmacol. 43:405–418.
   Google Scholar
• Sivaprakasam P, Wang Z, Meanwell NA, Khan JA, Langley DR, Johnson SR, Li G, Pendri A, Connolly TP, Gao M, et al. 2020. Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase. Bioorg Med Chem Lett. 30(22):127531.
   PubMed Web of Science ®Google Scholar
• Sonawane D, Reddy A, Jadav T, Sahu AK, Tekade RK, Sengupta P. 2021. Advancements in practical and scientific bioanalytical approaches to metabolism studies in drug development. Bioanalysis. 13(11):913–930.
   PubMed Web of Science ®Google Scholar
• Synold TW, Dussault I, Forman BM. 2001. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 7(5):584–590.
   PubMed Web of Science ®Google Scholar
• Takara K, Sakaeda T, Okumura K. 2006. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des. 12(3):273–286.
   PubMed Web of Science ®Google Scholar
• Takeshita A, Taguchi M, Koibuchi N, Ozawa Y. 2002. Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem. 277(36):32453–32458.
   PubMed Web of Science ®Google Scholar
• Tang J, Zhang L, Gao H, Liu Y, Zhang Q, Ran R, Zhang Z, He Q. 2016. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity. Drug Deliv. 23(4):1130–1143.
   PubMed Web of Science ®Google Scholar
• Terwogt JMM, Malingré MM, Beijnen JH, Wim W, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens J. 1999. Coadministration of oral cyclosporin a enables oral therapy with paclitaxel. Clin Cancer Res. 5(11):3379–3384.
   PubMed Web of Science ®Google Scholar
• Thelen K, Dressman JB. 2009. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 61(5):541–558.
   PubMed Web of Science ®Google Scholar
• Tkaczuk KHRJBcb, research c. 2011. Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer. Research c. 5:BCBCR. S5331.
   Google Scholar
• Venkatesh M, Wang H, Cayer J, Leroux M, Salvail D, Das B, Wrobel JE, Mani SJMp. 2011. In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol Pharmacol. 80(1):124–135.
   PubMed Web of Science ®Google Scholar
• Vogus DR, Evans MA, Pusuluri A, Barajas A, Zhang M, Krishnan V, Nowak M, Menegatti S, Helgeson ME, Squires TM, et al. 2017. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer. J Control Release. 267:191–202.
   PubMed Web of Science ®Google Scholar
• Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki R. 2001. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J Natl Cancer Inst. 93(16):1234–1245.
   PubMedGoogle Scholar
• Wada T, Gao J, Xie W. 2009. PXR and CAR in energy metabolism. Trends Endocrinol Metab. 20(6):273–279.
   PubMed Web of Science ®Google Scholar
• Waghray D, Zhang Q. 2018. Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment: miniperspective. J Med Chem. 61(12):5108–5121.
   PubMed Web of Science ®Google Scholar
• Walter-Sack I, Klotz UJCp. 1996. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet. 31(1):47–64.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang X, Tang Y, Zou J, Wang P, Zhang Y, Si W, Huang W, Dong X. 2018. A light-induced nitric oxide controllable release nano-platform based on diketopyrrolopyrrole derivatives for pH-responsive photodynamic/photothermal synergistic cancer therapy [https://doi.org/10.1039/C8SC03386B. Chem Sci. 9(42):8103–8109.
   PubMed Web of Science ®Google Scholar
• Wang PG, Xian M, Tang X, Wu X, Wen Z, Cai T, Janczuk A. 2002. Nitric oxide donors: chemical activities and biological applications. Chem Rev. 102(4):1091–1134.
   PubMed Web of Science ®Google Scholar
• Warburg OJS. 1956. On the origin of cancer cells. Science. 123(3191):309–314.
   PubMed Web of Science ®Google Scholar
• Ward AB, Szewczyk P, Grimard V, Lee C-W, Martinez L, Doshi R, Caya A, Villaluz M, Pardon E, Cregger C, et al. 2013. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc Natl Acad Sci USA. 110(33):13386–13391.
   PubMed Web of Science ®Google Scholar
• Wartmann M, Altmann K-A-C. 2002. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents. 2(1):123–148.
   PubMedGoogle Scholar
• Wilkinson G. 1997. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev. 27(2–3):129–159.
   PubMed Web of Science ®Google Scholar
• Willson TM, Kliewer S. 2002. PXR, CAR and drug metabolism. Nat Rev Drug Discov. 1(4):259–266.
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Gupta BK, Jaggi M, Chauhan S. 2010. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci. 351(1):19–29.
   PubMed Web of Science ®Google Scholar
• Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson D. 2013. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem. 288(44):31761–31771.
   PubMedGoogle Scholar
• Yang AK, He SM, Liu L, Liu JP, Wei MQ, Zhou SF. 2010. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem. 17(16):1635–1678.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Koizumi M, Adachi I, Kawakami JJF. 2006. Inhibition of P-glycoprotein-mediated transport by terpenoids contained in herbal medicines and natural products. Food Chem Toxicol. 44(12):2033–2039.
   PubMed Web of Science ®Google Scholar
• Zhitomirsky B, Assaraf Y. 2016. Lysosomes as mediators of drug resistance in cancer. Drug Resist Updat. 24:23–33.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Sanchez-Lopez E, Karin MJC. 2016. Autophagy, inflammation, and immunity: a troika governing cancer and its treatment. Cell. 166(2):288–298.
   PubMed Web of Science ®Google Scholar
• Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton J. 2003. Interactions of herbs with cytochrome P450. Drug Metab Rev. 35(1):35–98.
   PubMed Web of Science ®Google Scholar
• Zhou S, Lim LY, Chowbay B. 2004. Herbal modulation of P-glycoprotein. Drug Metab Rev. 36(1):57–104.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wen Q, Li SF, Zhang YF, Gao N, Tian X, Fang Y, Gao J, Cui MZ, He XP, et al. 2016. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. Oncotarget. 7(31):50612–50623.
   PubMedGoogle Scholar